BioCentury
ARTICLE | Company News

Champions Oncology, BC Cancer Agency deal

April 11, 2011 7:00 AM UTC

Champions Oncology (formerly Champions Biotechnology Inc.) exercised its 2010 option for exclusive, worldwide rights to develop and commercialize the agency's cancer candidate Irinophore C. The liposomal formulation of irinotecan is expected to start Phase I testing for advanced solid tumors in 4Q11. The exercise triggers an $85,000 payment to the agency, which is also eligible for undisclosed milestones and royalties. Champions said it is exploring strategic options to finance development costs of Irinophore C. ...